Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinpi Jiegu tablet is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Dalian Aosen Pharmaceutical (through its subsidiary Dalian Mingsen Pharmaceutical). The product is an oral finished formulation primarily indicated for the treatment of bone fractures and orthopedic injuries. The name 'Qinpi' refers to *Cortex Fraxini* (Ash Bark), a key component, while 'Jiegu' translates to 'bone-knitting' or 'bone-setting,' reflecting its therapeutic use in promoting bone healing. As a TCM product, it likely functions through a multi-component mechanism intended to reduce inflammation, alleviate pain, and stimulate osteoblastic activity to accelerate the formation of bone callus. It is currently approved and marketed in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinpi Jiegu tablet.